NCT04426435 is a Phase 2 clinical trial of honey based (HB) syrup in Breast Cancer, sponsored by Shiraz University of Medical Sciences.

Who is sponsoring NCT04426435?

NCT04426435 is sponsored by Shiraz University of Medical Sciences.

What drugs are being tested in NCT04426435?

Interventions in NCT04426435: honey based (HB) syrup.

What condition does NCT04426435 study?

NCT04426435 studies Breast Cancer.

Is NCT04426435 still recruiting?

NCT04426435 is currently completed. Last updated 8 October 2020.

Last reviewed 2020-10-08 · How we verify

NCT04426435

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects a Honey Based Syrup on Blood Parameters in Patients With Breast Cancer

Completed Phase 2 Last updated 8 October 2020

What this trial tests

Phase 2 trial testing honey based (HB) syrup in Breast Cancer in 60 participants. Completed in 5 October 2020.

Timeline

15 June 2020

Primary endpoint
25 September 2020

5 October 2020

Quick facts

Lead sponsor	Shiraz University of Medical Sciences
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	supportive care
Enrollment	60
Start date	15 June 2020
Primary completion	25 September 2020
Estimated completion	5 October 2020
Sites	1 location across Iran

Drugs / interventions tested

honey based (HB) syrup — full drug profile →

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Shiraz University of Medical Sciences

Who can join

Adults 18 to 70, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study aim Determination of the effect of a honey based (HB) syrup on the blood parameters of patients with breast cancer Design Two arm parallel group randomised clinical trial, double blinded Settings and conduct Design of the study: Women patients with breast cancer referring to Shohaday-e- Tajrish Hospital of Tehran who are under chemotherapy treatment. In order to blind the investigator, medications are named as "A" for syrup of HB and B for placebo. The patients don't aware of the type of drug they are assigned to. In addition, the groups are entered into statistical analysis as "A" and "B. The patients will revive either A or B syrup for 4 weeks. At the beginning of the trial demographic data would be gathered. Also, a blood sample would be drawn at the beginning time and after the end of intervention period (week 4). Data would be analysed by SPSS software using T-test.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Shiraz University of Medical Sciences trials

Trials by the same sponsor.

NCT07254221 — Rosuvastatin for Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients · Phase 4 · not yet recruiting
NCT06509893 — Ticagrelore Alone Post PCI · Phase 4 · recruiting
NCT05876819 — Quality of Care and Welfare Services for Disabled Middle Older Adults in Iran Lebanon · enrolling by invitation
NCT06979427 — CTFFR and Prediction of Non-Significant CAD Lesions · NA · recruiting
NCT05711004 — Efficacy of Education Via Phone-based Text Messaging (SMS) on Patients With Uncontrolled Hypertension · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04426435 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shiraz University of Medical Sciences
Last refreshed: 8 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04426435.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing